Please login to the form below
ulipristal acetate
This page shows the latest ulipristal acetate news and features for those working in and with pharma, biotech and healthcare.
FDA rejects Allergan’s uterine fibroid drug over safety concerns
Allergan’s selective progesterone receptor modulator is already approved in Europe, where it is sold as Esmya (ulipristal acetate) and marketed by Hungarian pharmaceutical company Gedeon Richter. ... next steps for ulipristal acetate NDA”.
Latest news
-
MHRA suspends new prescriptions of fibroid drug Esmya
Esmya (ulipristal acetate) is a selective progesterone receptor modulator billed as a safer and more effective pharmacological treatment for uterine fibroids than existing drugs such as AbbVie's Lupron (leuprolide acetate),
-
Bayer moves vilaprisan into phase III trials for uterine fibroids
Meanwhile, Allergan and Gedeon Richter plan to file their uterine fibroid drug ulipristal acetate in the US by the end of the year and Astellas is also busy in this area,
-
Allergan plans to file oral uterine fibroid drug in US by year-end
The studies of Allergan and Gedeon Richter's ulipristal acetate showed that the drug was able to reduce abnormal bleeding caused by uterine fibroids - also known as myomas - which can cause ... With two positive pivotal trials in hand, Allergan says it
-
Allergan on course to file uterine fibroid drug next year
A phase III trial of Allergan's uterine fibroid drug ulipristal acetate has met its targets, setting up a possible filing in 2017. ... Ulipristal acetate is a selective progesterone receptor modulator that could be a safer and more effective
-
Golin Health wins HRA Pharma and Atlantis Healthcare accounts
For HRA Pharma Golin will be working to raise awareness of the French company's emergency contraceptive pill ellaOne (ulipristal acetate) in the UK, targeting both pharmacists and women of childbearing
More from news
Approximately 2 fully matching, plus 9 partially matching documents found.
Latest Intelligence
-
The pill branding
In the UK, Levonelle with the active ingredient levonorgestrel and ellaOne containing ulipristal acetate are sold over the counter to girls over 16 since 2001. ... the binding landmark decision of switching the ellaOne (ulipristal acetate) pill to an OTC
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- World Health Organization releases latest set of COVID-19 guidelines
- BeiGene’s Brukinsa receives FDA approval for chronic lymphocytic leukaemia
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- Eli Lilly announces $450m investment in US manufacturing site
- Europe’s cancer community publishes new report on transforming patient care
- EU outlines measures to mitigate antibiotic shortage across Europe
- Innovative Trials comments on extra funding to increase access to clinical trials for cancer patients
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- JCVI recommends autumn COVID-19 vaccine booster for those at highest risk
- MIT researchers develop AI model to detect future lung cancer risk
- Merging global and local pharmacovigilance operations into a successful integrated approach
- Diversifying Healthcare AI with Federated Learning
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- World Health Organization releases latest set of COVID-19 guidelines
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- EU to revise pharmaceuticals law amid antibiotic shortages
- European MPs call for urgent action against antimicrobial resistance
- The role of medical communications in building credibility for healthtech
PMHub
Healthcare Media Europe – HME Ltd
HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...
Latest intelligence
- Virtual Steering Committee & Peer Influence Program
- In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
- Meeting healthcare’s rising challenges
- The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
- Report gives insights to address gaps in HCP engagement
- How does Pharma-HCP engagement need to evolve in today's digital landscape?...
